Apoptosis in prostatic adenocarcinomas: A study of relationship to Ki-67 and Bcl-2 protein expression

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 1111-1116

  Tanji, Nozomu ^a   Yokoyama, Masayoshi ^a   Sugamoto, Takao ^a   Takeuchi, Masafumi ^a   Terada, Nobuyuki ^b  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bcl 2; Ki 67; Prostatic cancer

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL DIVISION; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0031839536     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Arends MJ and Wyllie AH: Apoptosis: mechanisms and roles in pathology. Int Rev Exp Pathol 32: 223-254, 1991.
2. Kerr JFR, Winterford CM and Harmon BV: Apoptosis: its significance in cancer and cancer therapy. Cancer 73: 2013-2026, 1994.
3. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
4. Aihara M, Truong LD, Dunn JK et al: Frequency of apoptolic bodies positively correlates grade in prostate cancer. Hum Pathol 25: 797-801, 1994.
5. Aihara M, Scardino PT, Truong LD et al: The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 75: 522-529, 1995.
6. Gaffney EF: The extent of apoptosis in different types of high grade prostatic carcinoma. Histopathology 25: 269-273, 1994.
7. Westin P, Stattin P, Damber J-E et al: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146: 1368-1375, 1995.
8. Meyer JS, Sufrin G and Martin SA: Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J Urol 128: 1353-1356, 1982.
9. Nemoto R, Uchida K, Shimazui T et al: Immunohistochemical demonstration of S phase cells by anti-bromodeoxyuridine monoclonal antibody in human prostate adenocarcinoma. J Urol 141: 337-340, 1989.
10. Raymond WA, Leong AS-Y, Bolt JW et al: Growth fraction in human prostatic carcinoma determined by Ki-67 immunostaining. J Pathol 156: 161-167, 1988.
11. Bakhshi A, Jensen JP, Goldman P et al: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 889-906, 1985.
12. Clearly ML and Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82: 7439-7443, 1985.
13. Tsujimoto Y, Gorham J, Cossman J et al: The t(14; 18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science (Washington DC) 229: 1390-1393, 1985.
14. Hockenbery D, Nunez G. Milliman G et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
15. Colombel M, Symmans F, Gil S et al: Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
16. McDonnell TJ, Troncoso P, Brisbay SM et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
17. Segal NH, Cohen RJ, Haffejee Z et al: Bcl-2 proto-oncogene prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 118: 616-618, 1994.
18. Japanese Urological Association and the Japanese Pathological Society eds. General Rule for Clinical and Pathological Studies on Prostatic Cancer in Japan (2nd ed.) (in Japanese). Tokyo, Kanehara Publishing Co., 1992, pp 66.
19. Mostofi FK, Sesterhenn I and Sobin LH: Histological Typing of Prostatic Tumours. International Histological Classification of Tumours (No 22 Geneva). World Health Organization, 1980
20. Wyllie AH, Kerr JFR and Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306, 1980.
21. Gerdes J, Scwab U, Lemke H et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983.
22. Gerdes J, Lemke H, Baish H et al: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
23. Cher ML, Chew K, Rosenau W et al: Cellular proliferation in prostatic adenocarcinoma as assayed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 26: 87-93, 1995.
24. Gallee MPW, Visser-de Jong E, Ten Kate FJW et al: Monoclonal antibody Ki-67 defined growth fraction in beneign prostatic hyperplasia and prostatic cancer. J Urol 142: 1342-1346, 1989.
25. Montironi R, Galluzzi CM, Scarpelli M et al: Occurrence of cell death (apoptosis) in prostatic intra-epithelial neoplasia. Virchows Archiv A (Pathol Anat) 423: 351-357, 1993.
26. Hockenbery DM, Zutter M, Hickey W et al: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991.